Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “buy” rating reiterated by BTIG Research in a research report issued to clients and investors on Wednesday. They presently have a $24.00 target price on the stock. BTIG Research’s price target points to a potential upside of 53.06% from the company’s previous close.

Several other brokerages have also weighed in on TEVA. BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a report on Wednesday, July 5th. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 price objective for the company. in a report on Tuesday, July 4th. Wells Fargo & Company reissued a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday, June 27th. Jefferies Group LLC restated a “hold” rating and issued a $33.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. Finally, Cantor Fitzgerald set a $31.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Five investment analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and an average target price of $28.72.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.68 on Wednesday. The company has a 50-day moving average of $16.94 and a 200-day moving average of $26.89. The stock’s market capitalization is $15.93 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $45.85. Teva Pharmaceutical Industries Limited also saw unusually large options trading activity on Wednesday. Investors acquired 29,656 put options on the stock. This is an increase of 231% compared to the average daily volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.25 earnings per share. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by BTIG Research” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/06/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-btig-research.html.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Greylin Investment Mangement Inc. grew its position in Teva Pharmaceutical Industries Limited by 36.9% during the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock valued at $9,783,000 after purchasing an additional 79,300 shares in the last quarter. Financial Counselors Inc. grew its position in Teva Pharmaceutical Industries Limited by 5.7% during the second quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock valued at $4,671,000 after purchasing an additional 7,571 shares in the last quarter. PGGM Investments grew its position in Teva Pharmaceutical Industries Limited by 12.0% during the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock valued at $50,763,000 after purchasing an additional 163,292 shares in the last quarter. GAM Holding AG grew its position in Teva Pharmaceutical Industries Limited by 23.2% during the second quarter. GAM Holding AG now owns 41,900 shares of the company’s stock valued at $1,392,000 after purchasing an additional 7,900 shares in the last quarter. Finally, Federated Investors Inc. PA grew its position in Teva Pharmaceutical Industries Limited by 34,112.9% during the second quarter. Federated Investors Inc. PA now owns 228,542 shares of the company’s stock valued at $7,592,000 after purchasing an additional 227,874 shares in the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.